Indorama to acquire Huntsman’s chemical intermediates and surfactants units

TAGS

US chemical manufacturing company has agreed to divest its chemical intermediates businesses, which includes PO/MTBE, and its surfactants businesses to Thai petrochemicals producer for $2.076 billion.

The deal is expected to help Huntsman to focus on its growing polyurethanes operations while enabling Indorama Ventures to increase its US footprint.

As part of the deal, the Thai chemical company will acquire Huntsman’s production plants situated in Port Neches, Texas; Dayton, Texas; Chocolate Bayou, Texas, US; Ankleshwar, ; and Botany, Australia.

The acquisition is expected to strengthen Indorama Ventures’ Integrated Oxides (EOs) and Specialty Chemical segment’s growth trajectory and includes EODs and Propylene Oxide Derivatives.

See also  Martin Midstream Partners sells Stockton Sulfur Terminal to Gulf Terminals

Furthermore, Indorama Ventures will expand its expertise of operating Integrated Oxides facilities in the US Gulf Coast (USGC).

Huntsman to sell chemical intermediates and surfactants businesses to Indorama Ventures

Huntsman to sell chemical intermediates and surfactants businesses to Indorama Ventures. Image courtesy of supakitmod at FreeDigitalPhotos.net

The transaction consideration includes cash purchase price of $2.0 billion plus the transfer of up to approximately $76 million in net underfunded pension and other post-employment benefit liabilities.

– Chairman, President and CEO of Huntsman said: “This is another milestone in our stated strategy to focus more on our downstream and specialty businesses where we will generate more stable margins and consistent, strong free cash flow.

See also  Grasim Industries, Lubrizol to kickstart construction of CPVC resin facility this year

“We are committed to retaining our strong investment grade balance sheet, repurchasing our shares, investing in organic research and select capacity expansions and acquiring strategic assets that are accretive to our earnings and create shareholder value.

“Huntsman intends to accelerate share repurchases under its existing $1 billion multi-year authorization after the close of this transaction.”

The transaction will be funded by internal cash flows and debt financing and does not necessitate equity dilution, according to Indorama Ventures.

See also  FDA approves Genentech’s Xolair for food allergies: A new horizon in allergy treatment

Aloke Lohia – Indorama Ventures Group CEO said: “This acquisition is a momentous propellant in our journey towards our stated goal of being a global, diversified chemicals company with multiple, and related earnings streams.”

Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by Q4 2019.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This